About: Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia
Creator	Gao, Fei Bai, Chen Gu, Xiaohong Huang, Ling Liu, Tiegang Ma, Xueyan Wan, Yuxiang Yu, He Xu, Jingnan Zheng, Zian
source	Medline; PMC
abstract	BACKGROUND: Pneumonia is a common respiratory disorder, which brings an enormous financial burden to the medical system. However, the current treatment options for pneumonia are limited because of drug resistance and side effects. Our previous study preliminarily confirmed that Yinlai Decoction (YD), a common prescription for pneumonia in clinical practice, can regulate the expression of inflammatory factors, but the mechanisms are unknown yet. METHODS: In our work, a method named network pharmacology was applied, which investigated the underlying mechanisms of herbs based on a variety of databases. We obtained bioactive ingredients of YD on TCMSP database and collected potential targets of these ingredients by target fishing. Then the pneumonia-related targets database was built by TTD, Drugbank, HPO, OMIM, and CTD. Based on the matching targets between YD and pneumonia, the PPI network was built by STRING to analyze the interactions among these targets and then input into Cytoscape for further topological analysis. DAVID and KEGG were utilized for GO and pathway enrichment analysis. Then rat model based on LPS stimulated pneumonia was used to verify the possible mechanism of YD in treating pneumonia. RESULTS: Sixty-eight active ingredients, 103 potential targets and 8 related pathways, which likely exert a number of effects, were identified. Three networks were constructed using Cytoscape, which were herb-component-network, YD-pneumonia target network, and herb-component-YD target-pneumonia network. YD was verified to treat LPS-induced pneumonia by regulating the inflammatory factor IL-6, which was a predicted target. CONCLUSION: Network analysis indicated that YD could alleviate the symptoms and signs of pneumonia through regulating host immune inflammatory response, angiogenesis and vascular permeability, the barrier function of the airway epithelial cells, hormone releasing and cell growth, proliferation, and apoptosis.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1186/s12906-020-02954-z
bibo:pmid	32493296
has license	cc-by
sha1sum (hex)	b5692a2317cb554affb5c3e4d6326aa4b7a3badc
schema:url	https://doi.org/10.1186/s12906-020-02954-z
resource representing a document's title	Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia
has PubMed Central identifier	PMC7267769
has PubMed identifier	32493296
schema:publication	BMC Complement Med Ther
resource representing a document's body	covid:b5692a2317cb554affb5c3e4d6326aa4b7a3badc#body_text
is schema:about of	named entity 'limited' named entity 'common' named entity 'interactions' named entity 'herbs' named entity 'mechanisms' named entity 'PHARMACOLOGY' named entity 'LIMITED' covid:arg/b5692a2317cb554affb5c3e4d6326aa4b7a3badc named entity 'database' named entity 'OMIM' named entity 'network' named entity 'Pneumonia' named entity 'system' named entity 'verify' named entity 'LPS' named entity 'pneumonia' named entity 'pharmacology' named entity 'pneumonia' named entity 'respiratory disorder' named entity 'treatment options' named entity 'pneumonia' named entity 'cell receptor' named entity 'influenza' named entity 'oral bioavailability' named entity 'pneumonia' named entity 'respiratory diseases' named entity 'KEGG' named entity 'dendritic cells' named entity 'pneumonia' named entity 'lipopolysaccharide' named entity 'TLRs' named entity 'atomization' named entity 'administrated' named entity 'pneumonia' named entity 'phenotype' named entity 'bioactive' named entity 'TLRs' named entity 'lung diseases' named entity 'inflammatory response' named entity 'cell wall' named entity 'bioactive' named entity 'holistic' named entity 'pneumonia' named entity 'respiratory epithelial' named entity 'epithelial cell' named entity 'Therapeutic Target' named entity 'biological processes' named entity 'multiple systems' named entity 'oral route' named entity 'long time' named entity 'infection' named entity 'drug product' named entity 'pneumonia' named entity 'Peucedanum' named entity 'anti-bacterial' named entity 'multi-target' named entity 'EGFR' named entity 'lung' named entity 'Th17' named entity 'Caco-2' named entity 'signal transduction' named entity 'Therapeutic effect' named entity 'infection' named entity 'kaempferol' named entity 'TCM' named entity 'pneumonia' named entity 'Traditional Chinese medicine' named entity 'betweenness centrality' named entity 'drug resistance' named entity 'angiogenesis' named entity 'quercetin' named entity 'Sprague-Dawley'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software